US 11,744,836 B2
Dry powder treprostinil for the treatment of pulmonary hypertension
Robert Frank Roscigno, Melbourne Beach, FL (US); Brian T. Farrer, Apex, NC (US); Jacob J. Sprague, Cary, NC (US); and Benjamin Maynor, Durham, NC (US)
Assigned to Liquidia Technologies, Inc., Morrisville, NC (US)
Filed by LIQUIDIA TECHNOLOGIES, INC., Morrisville, NC (US)
Filed on Jul. 30, 2021, as Appl. No. 17/390,514.
Application 17/390,514 is a continuation of application No. 17/104,348, filed on Nov. 25, 2020.
Application 17/104,348 is a continuation of application No. 16/099,135, granted, now 10,898,494, issued on Jan. 26, 2021, previously published as PCT/US2017/031301, filed on May 5, 2017.
Claims priority of provisional application 62/472,204, filed on Mar. 16, 2017.
Claims priority of provisional application 62/440,078, filed on Dec. 29, 2016.
Claims priority of provisional application 62/404,960, filed on Oct. 6, 2016.
Claims priority of provisional application 62/332,013, filed on May 5, 2016.
Prior Publication US 2021/0353641 A1, Nov. 18, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/5575 (2006.01); A61P 9/12 (2006.01); A61K 31/557 (2006.01); A61K 9/00 (2006.01); A61K 9/48 (2006.01); A61K 47/02 (2006.01); A61K 47/18 (2017.01); A61K 47/26 (2006.01)
CPC A61K 31/557 (2013.01) [A61K 9/0075 (2013.01); A61K 9/4858 (2013.01); A61K 31/5575 (2013.01); A61P 9/12 (2018.01); A61K 47/02 (2013.01); A61K 47/183 (2013.01); A61K 47/26 (2013.01)] 21 Claims
 
1. A system for treating pulmonary arterial hypertension, the system comprising:
a dry powder inhaler; and
a dose of dry powder particles comprising treprostinil or a pharmaceutically acceptable salt thereof, and an excipient matrix;
wherein the dry powder particles are formed from a solution comprising a pH modifying agent and a bulking agent;
wherein the dry powder particles are filled into one or more dosage units configured to be inserted into the dry powder inhaler for administration to a patient; and
wherein the one or more dosage units include a total predetermined amount of the treprostinil or the pharmaceutically acceptable salt thereof in the range of 100 μg to 350 μg.